There is a paucity of data on the role of microglia and neuroinflammatory processes in the association between chronic pain and depression. The current study examined the effect of the microglial inhibitor minocycline on depressive-like behaviour, spinal nerve ligation (SNL)-induced mechanical and cold allodynia and associated changes in the expression of genes encoding microglial markers (M1 vs. M2 polarisation) and inflammatory mediators in the prefrontal cortex in the olfactory bulbectomised (OB) rat model of depression. Acute minocycline administration did not alter OB-induced depressive-like behaviour but prevented SNL-induced mechanical allodynia in both OB and sham rats. In comparison, chronic minocycline attenuated OB-induced depressive-like behaviour and prevented the development of SNL-induced mechanical allodynia in OB, but not sham, rats. Further analysis revealed that SNLinduced mechanical allodynia in OB rats was attenuated by chronic minocycline at almost all time-points over a 2 week testing period, an effect observed only from day 10 post-SNL in sham rats. Chronic administration of minocycline reduced the expression of CD11b, a marker of microglial activation, and the M1 pro-inflammatory cytokine IL-1b, in the prefrontal cortex of sham-SNL animals. In comparison, the expression of the M2 microglia marker (MRC2) and anti-inflammatory cytokine IL-10 was increased, as were IL-1b, IL-6 and SOCS3, in the prefrontal cortex of OB-SNL animals following chronic minocycline. Thus, chronic minocycline attenuates neuropathic pain behaviour and modulates microglial activation and the central expression of inflammatory mediators in a manner dependent on the presence or absence of a depressive-like phenotype.
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Introduction
Depression and chronic pain are widely recognised clinical comorbidities, with up to 50% of chronic pain patients exhibiting depression (Radat et al., 2013) , while almost 60% of depressed patients experience painful physical symptoms (Aguera-Ortiz et al., 2011). Recent data from animal studies support this clinical relationship and indicate that inflammatory and neuropathic pain-related responding is enhanced in various animal models of depression including olfactory bulbectomy (OB) (Burke et al., 2013a (Burke et al., , 2010 , early life stress (Uhelski and Fuchs, 2010; Burke et al., 2013b) and the Wistar-Kyoto rat (Burke et al., 2010; Zeng et al., 2008; Rea et al., 2014) . However, the neurobiological substrates mediating altered nociceptive responding in depression remain ambiguous. Substantial evidence indicates dysregulation of the (neuro)immune system in both depression and chronic pain (for review see Miller et al., 2009; Watkins and Maier, 2005) ; which may also underlie the association between these conditions. Preclinical studies have demonstrated peripheral nerve injury-induced neuroimmune activation in brain regions responsible for the modulation of nociception and/or affect, including the prefrontal cortex (Apkarian et al., 2006; Al-Amin et al., 2011) . Furthermore, the expression of genes coding for the pro-inflammatory cytokines IL-1b, IL-6 and/or TNFa, is enhanced in brain regions responsible for processing emotion and pain in animal models of depression with concomitant inflammatory (Kim et al., 2012; Arora et al., 2011) and neuropathic (Norman et al., 2010; Apkarian et al., 2006; Burke et al., 2013a,b) pain-related responding. Thus, modulating neuroimmune responses has been proposed as a novel target for the treatment of CNS disorders with an inflammatory component, including depression and associated chronic pain.
Antidepressant efficacy of minocycline, a second-generation antibiotic that also inhibits microglial activation, has been reported both clinically (Miyaoka et al., 2012) 
